Oral and Parenteral Glutamine in Bone Marrow Transplantation: A Randomized, Double-Blind Study

1999 ◽  
Vol 23 (3) ◽  
pp. 117-122 ◽  
Author(s):  
Paul R. Schloerb ◽  
Barry S. Skikne
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind

Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital

2002 ◽  
Vol 49 (suppl_1) ◽  
pp. 51-55 ◽  
Author(s):  
Olle Ringdén
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Amphotericin B ◽  
Marrow Transplantation ◽  
Fungal Infections ◽  
University Hospital ◽  
Fungal Colonization ◽  
Double Blind Study ◽  
Transplant Recipients ◽  
Double Blind

Abstract Our substantial experience in several trials with AmBisome in adult and paediatric patients undergoing transplantation has shown this formulation of amphotericin B to be safe and effective in therapeutic and prophylactic use. AmBisome has shown a significant reduction in fungal colonization and invasive Candida infections compared with placebo in a prospec-tive, double-blind study in bone marrow transplantation, and eradication of invasive fungal infections in 86% of 14 children undergoing bone marrow transplantation. The main side effects of AmBisome use are elevations in serum potassium and creatinine, but these lead to very few withdrawals from treatment. Compared with conventional amphotericin B, AmBisome is very expensive, but its much improved safety profile and proven efficacy make it an excellent agent for management of invasive fungal disease in transplant recipients.

Sign in / Sign up

Export Citation Format

Share Document